Share This Page
Drug Price Trends for MUCUS ER
✉ Email this page to a colleague

Average Pharmacy Cost for MUCUS ER
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
MUCUS ER 600 MG TABLET | 46122-0416-60 | 0.35297 | EACH | 2025-01-22 |
MUCUS ER 600 MG TABLET | 46122-0416-60 | 0.34521 | EACH | 2024-12-18 |
MUCUS ER 600 MG TABLET | 46122-0416-60 | 0.39928 | EACH | 2024-11-20 |
MUCUS ER 600 MG TABLET | 46122-0416-60 | 0.32011 | EACH | 2024-10-23 |
MUCUS ER 600 MG TABLET | 46122-0416-60 | 0.35791 | EACH | 2024-09-18 |
MUCUS ER 600 MG TABLET | 46122-0416-60 | 0.30672 | EACH | 2024-08-21 |
MUCUS ER 600 MG TABLET | 46122-0416-60 | 0.34840 | EACH | 2024-07-17 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Expectorant Drugs: Focus on Mucus Relief
Market Size and Overview
The global expectorant drugs market, which includes products like Mucus Relief, is poised for significant growth. As of 2023, the market was valued at approximately $16.8 billion and is projected to reach $22.9 billion by 2030, growing at a CAGR of 4.5%[1][3][5].
Market Growth Drivers
Rising Prevalence of Respiratory Disorders
The increasing prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and bronchitis is a primary driver for the growing demand for expectorant drugs. These conditions affect millions worldwide, leading to a heightened need for effective symptom management and relief[1][3][5].
Pandemics and Respiratory Health
Pandemics like COVID-19 have underscored the importance of maintaining good respiratory health. This has led to increased awareness and demand for respiratory health products, including expectorant drugs. Government initiatives to improve respiratory health are also expected to benefit the pharmaceutical companies producing these medications[3].
Key Market Segments
Drug Type
Guaifenesin, a common active ingredient in expectorant drugs like Mucus Relief, dominated the drug type segment in 2023, holding over 47.9% of the market share. Guaifenesin works by thinning the mucus, making it easier to clear from the airways[5].
Formulation and Administration
Tablets are the most popular formulation for expectorant drugs, capturing more than 40.5% of the market share in 2023. Oral administration is the preferred route, accounting for over 68.5% of the market share[5].
Price Analysis for Mucus Relief
Current Pricing
The cost for Mucus Relief 400 mg oral tablets is around $11 for a supply of 60 tablets, depending on the pharmacy. Generic versions of guaifenesin, the active ingredient in Mucus Relief, are available at lower prices, such as $9.90 for 20 tablets[2].
Discount Programs
Consumers can use discount cards, like the Drugs.com Discount Card, to save up to 80% or more off the cost of prescription and over-the-counter medications, including Mucus Relief. This card is accepted at major pharmacy chains across the U.S.[2].
Market Projections
Revenue Growth
The global expectorant drugs market is expected to grow significantly over the next decade. By 2030, the market is projected to reach $22.9 billion, with a CAGR of 4.5% from 2023 to 2030[1]. Another projection suggests the market could reach $27.8 billion by 2033, growing at a CAGR of 5.2% from 2024 to 2033[5].
Regional Market Share
North America held the largest market share in 2023, representing 32.2% of the global expectorant drugs market, valued at $5.41 billion. This region is expected to continue its dominance due to high healthcare spending and a large patient population suffering from respiratory disorders[5].
Impact of Respiratory Disorders on Market Demand
Chronic Obstructive Pulmonary Disease (COPD)
COPD was the leading indication for expectorant drugs in 2023, with a 35.4% market share. As COPD and other respiratory diseases continue to affect a growing number of people, the demand for expectorant drugs like Mucus Relief is expected to increase[5].
Asthma and Bronchitis
Asthma and bronchitis also contribute significantly to the demand for expectorant drugs. These conditions often result in excessive mucus production, which can be managed effectively with expectorants. The rising prevalence of these diseases ensures a steady and growing market for these medications[1][3][5].
Consumer Trends and Preferences
Preference for Oral Administration
Oral administration remains the preferred route for expectorant drugs, accounting for over 68.5% of the market share. This preference is driven by the ease of use and the effectiveness of oral formulations in managing respiratory symptoms[5].
Generic and Over-the-Counter Options
The availability of generic versions of expectorant drugs and over-the-counter options like Mucus Relief has made these medications more accessible and affordable for consumers. This trend is expected to continue, driving market growth[2].
Key Takeaways
- The global expectorant drugs market is projected to reach $22.9 billion by 2030, growing at a CAGR of 4.5% from 2023 to 2030.
- Guaifenesin, the active ingredient in Mucus Relief, dominates the drug type segment with over 47.9% market share.
- Oral administration and tablet formulations are the most preferred.
- North America holds the largest market share, driven by high healthcare spending and a large patient population.
- The increasing prevalence of respiratory disorders like COPD, asthma, and bronchitis drives the demand for expectorant drugs.
FAQs
What is the projected market size for expectorant drugs by 2030?
The global expectorant drugs market is projected to reach $22.9 billion by 2030, growing at a CAGR of 4.5% from 2023 to 2030[1].
What is the primary active ingredient in Mucus Relief?
The primary active ingredient in Mucus Relief is guaifenesin, which works by thinning the mucus to make it easier to clear from the airways[2][5].
How much does Mucus Relief typically cost?
The cost for Mucus Relief 400 mg oral tablets is around $11 for a supply of 60 tablets, depending on the pharmacy. Generic versions can be even cheaper, starting from $9.90 for 20 tablets[2].
What are the main drivers for the growth of the expectorant drugs market?
The main drivers include the rising prevalence of respiratory disorders such as COPD, asthma, and bronchitis, as well as increased awareness and government initiatives to improve respiratory health[1][3][5].
Which region holds the largest market share for expectorant drugs?
North America holds the largest market share, representing 32.2% of the global expectorant drugs market, valued at $5.41 billion in 2023[5].
What is the preferred route of administration for expectorant drugs?
Oral administration is the preferred route, accounting for over 68.5% of the market share[5].
Sources
- GlobeNewswire: "Expectorant Drugs Market Poised to Reach US$22.9 Billion by 2030 with a Steady 4.5% CAGR - Persistence Market Research"[1].
- Drugs.com: "Mucus Relief Prices, Coupons, Copay Cards & Patient Assistance"[2].
- Future Market Insights: "Global Expectorant Drugs Market Growth Projection 2024-2034"[3].
- Coborns Marketplace: "TopCare Mucus ER, Maximum Strength, 1200 mg, Extended Release Tablets"[4].
- Market.us: "Expectorant Drugs Market Size, Share | CAGR Of 5.2%"[5].
More… ↓